Effect of a multilevel implementation programme on shared decision-making in breast cancer care

H. van Veenendaal 1,2*, H. R. Voogdt-Pruis 2,3, D. T. Ubbink 4 and C. G. J. M. Hilders 1,5

1 Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands
2 Dutch Association of Oncology Patient Organizations, Utrecht, the Netherlands
3 Department of Global Health, University Medical Centre Utrecht, Utrecht, the Netherlands
4 Department of Surgery, Amsterdam University Medical Centre, Amsterdam, the Netherlands
5 Reinier de Graaf Hospital, Delft, the Netherlands

*Correspondence to: Erasmus School of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, the Netherlands (e-mail: haskevanveenendaal@gmail.com)

Abstract

Background: Women with newly diagnosed breast cancer face multiple treatment options. Involving them in a shared decision-making (SDM) process is essential. The aim of this study was to evaluate whether a multilevel implementation programme enhanced the level of SDM behaviour of clinicians observed in consultations.

Methods: This before–after study was conducted in six Dutch hospitals. Patients with breast cancer who were facing a decision on surgery or neoadjuvant systemic treatment between April 2016 and September 2017 were included, and provided informed consent. Audio recordings of consultations made before and after implementation were analysed using the five-item Observing Patient Involvement in Decision-Making (OPTION-5) instrument to assess whether clinicians adopted new behaviour needed for applying SDM. Patients scored their perceived level of SDM, using the nine-item Shared Decision-Making Questionnaire (SDM-Q-9). Hospital, duration of the consultation(s), age, and number of consultations per patient that might influence OPTION-5 scores were investigated using linear regression analysis.

Results: Consultations of 139 patients were audiotaped, including 80 before and 59 after implementation. Mean (s.d.) OPTION-5 scores, expressed on a 0–100 scale, increased from 38.3 (15.0) at baseline to 53.2 (14.8) 1 year after implementation (mean difference (MD) 14.9, 95 per cent c.i. 9.9 to 19.9). SDM-Q-9 scores of 105 patients (75.5 per cent) (72 before and 33 after implementation) were high and showed no significant changes (91.3 versus 87.6; MD –3.7, –9.3 to 1.9). The implementation programme had an association with OPTION-5 scores ($\beta = 14.2$, $P < 0.001$), hospital ($\beta = 2.2$, $P = 0.002$), and consultation time ($\beta = 0.2$, $P < 0.001$).

Conclusion: A multilevel implementation programme supporting SDM in breast cancer care increased the adoption of SDM behaviour of clinicians in consultations.

Introduction

Approximately 14 000 Dutch women are diagnosed with breast cancer every year. The emotional stress following a diagnosis of breast cancer has been shown to affect both patient information recall and the decision-making process. Ideally, clinicians should help patients to achieve an informed decision that best fits their personal preferences, circumstances, and concerns by involving these patients in a shared decision-making (SDM) process. SDM has been promoted in cancer care for many years. Despite the need for SDM, its implementation in clinical practice remains a challenge. In general, clinicians either find it difficult to apply SDM, think that they already involve patients in decisions, or do not consider SDM key to their clinical role. Practical problems, such as lack of time, perceived lack of applicability due to patient characteristics or the clinical situation, and a poor fit into workflow can all negatively influence implementation of SDM.

Particularly in breast cancer care, implementing SDM is even more challenging, given the many treatment options available. Clinicians must explain the risks associated with various treatments and help patients to value the different options available. Multiple decisions must be made over an extended period of time and involve different clinicians working within a team. Observed levels of SDM behaviour during breast cancer consultations show considerable room for improvement. Clinicians often fail to communicate to the patient that a decision needs to be made. A focus on ‘fighting’ the cancer may inhibit the process of valuing different treatment options, and also in considering long-term consequences.

Interventions that have been proposed to promote SDM involve training clinicians (including the participation of patients) and using decision aids, providing feedback on performance in consultations, incorporating time-outs in care pathways, and use of incentives. In the oncology setting, suggested interventions include implementing decision aids, acknowledging uncertainty, incorporating the patient’s values and preferences into SDM, involving caregivers, and making allowances for the additional time required for SDM.
The aim of this study was to evaluate whether a multilevel SDM implementation programme would actually help clinicians to adopt new behaviour needed for applying SDM in daily breast cancer care, and to investigate whether a potential change in clinical behaviour was noticed by patients.

**Methods**

An unpaired before–after implementation study was used to evaluate whether a multilevel implementation programme would enhance the level of SDM of clinicians observed in consultations in a clinical outpatient setting, using the Standards for Reporting Implementation Studies (StaRI) as a guideline.

**Study population and selection**

Seven breast cancer outpatient clinics of hospitals in the Utrecht region of the Netherlands were asked to participate in the study. Six hospitals were included (1 university hospital, 2 teaching hospitals, and 3 general hospitals). One hospital declined to participate, as doctors were not convinced the implementation would further improve their level of SDM. All clinicians involved in the decision process with the patient regarding surgical or neoadjuvant treatments were invited to participate in the study.

The recruitment of all consecutive patients with newly diagnosed breast cancer, and who faced a treatment decision, took place between July 2016 and October 2016 (preimplementation), and between April 2017 and August 2017 (postimplementation). Each patient was informed about the study and completed an informed consent form. Each patient was included only once. Patients who did not speak Dutch were excluded, unless they were accompanied by a person who spoke Dutch fluently. Approval for the study was obtained from the medical research ethics committee (W16.019).

**Implementation programme**

A theoretical framework for implementation was used for the design of the programme. Responding to barriers to and facilitators of implementation at each of four implementation levels supports the design of an effective implementation. Four levels were used, and key factors for effective SDM implementation were incorporated into the programme (Table S1, supplementary material).

**Innovation: the concept of SDM**

To help clinicians grasp what SDM entails for their behaviour during consultations, clinicians were asked repeatedly to reflect, using a practical four-step model for applying SDM, on their communication behaviour during feedback sessions, training, and in daily practice.

**Users of the innovation**

Personal and team feedback on SDM behaviour was provided, followed by interdisciplinary team training.

**Organizational context**

Teams looked at the allocation of time (time-outs) for SDM in clinical care pathways. Rapid cycle learning was included by explaining the plan–do–study–act cycle, and by encouraging teams to experiment with new ways of working and sharing their experiences at collaborative meetings and via the researchers. The programme was tailored to the local context: each breast cancer team defined their goals within the scope of the programme and selected tools to support the implementation of SDM.

**Sociopolitical context**

Concurrent activities that might influence the level of SDM were monitored via a logbook. A clinician from each team, together with one of the researchers, kept this logbook. Patients were involved during all phases of the programme.

**Data collection**

All consultations relevant to the decision-making process — meaning one or more consultations conducted by one or more clinicians from the team to make one decision about breast cancer treatment — were audiotaped. Physicians and patients were aware of this and were instructed to proceed with their consultation as normal (preintervention) or to apply what they had learnt during the intervention (postintervention).

As the primary outcome measure, the OPTION-5 was used to rate clinicians’ performance in terms of involving patients in the decision-making process during real-life consultations.

The OPTION-5 instrument is deemed suitable for use in oncology practice and scores five key decision-making behaviours. Each of the five items were rated on a scale ranging from 0 (no effort made) to 4 (exemplary effort made), and the overall mean score was expressed on a scale of 0–100. This score reflects the extent to which the clinician showed the communicative behaviour needed to involve patients in the decision-making process. Higher scores indicate better SDM behaviour during the consultation; a minimum improvement of 10 points was considered clinically meaningful.

The secondary outcome measure was the patients’ perceived level of SDM during the medical consultation(s), as measured with the SDM-Q. The nine statements were rated on a six-point Likert-type scale ranging from ‘completely disagree’ (0) to ‘completely agree’ (5). These questions were completed at the end of the final consultation when a decision about breast cancer treatment was made. The scores of the 9 items per patient were added up and multiplied with 20/9 to provide a percentage of the maximum score, ranging from 0 (no SDM) to 100 (maximum level of SDM). A maximum of two missing items were imputed from the mean of items that were scored. Questionnaires were excluded when the patient left three or more items unanswered.

**Sample size calculation**

A preintervention mean score of 39 was assumed, which is high compared with that in other studies. A relatively high score was anticipated because of the considerable variation in means across breast cancer studies, and because two-way communication in (breast) cancer care is already considered important. A total sample size of 120 patients was calculated, based on an increase in OPTION-5 score from 39 before implementation to 49 after implementation, with a standard deviation of 13, an intracluster correlation of 0.01 (to correct for interhospital differences), an of 0.05, a power of 80 per cent, and an effect size of 0.77. The aim was to include a total of 180 patients to account for possibly failed recordings or dropout of teams.

**Data analysis**

Three raters applied the OPTION-5 coding scheme, refined for vascular surgery and oncology. The manual was adjusted to be relevant for breast cancer surgery in order to decrease raters’ uncertainty in scoring the audio recordings (Table 1). The first
Statistics

OPTION-5 score. Statistical analysis was carried out using SPSS version 17.0 (IBM, Armonk, NY, USA). Differences are expressed as mean differences (MDs) with their 95 per cent confidence intervals. Pearson’s $\chi^2$ statistic was used to analyse differences between categorical variables. The implementation programme, duration of the consultation(s), hospital/team (number of recordings, starting level, composition), age, and number of consultations per patient before and after implementation were included in the regression model for theOPTION-5 score. Statistical analysis was carried out using SPSS Statistics® v. 17.0 (IBM, Armonk, NY, USA). $P < 0.050$ (two-sided) was considered statistically significant.

### Results

Six of the seven hospitals approached participated in the study. One hospital declined to take part. One of the six participating hospital teams did not perform the postintervention measurement because they thought that feedback from a new series of consultations would not improve their practice further.

Twenty-two clinicians (surgeons, nurses, nurse specialists) participated in both measurements, and six clinicians (four nurse specialists, two nurses) participated only in the postimplementation measurement. The participating clinicians before and after the implementation were similar with regard to background and education. The logbook showed that hospital teams did not participate in any concurrent activities unrelated to the programme that may have influenced the level of SDM. Four hospital teams adjusted their clinical pathway and/or appointment scheduling to allow for the implementation of SDM and to incorporate the time needed for patients to reflect on their decisions.

Patients’ ages ranged from 32 to 91 (mean 62.3) years. The options discussed were mastectomy, lumpectomy, radiotherapy, neoadjuvant chemotherapy, and conservative treatment. Other options related to these decisions, such as breast reconstruction, the use of cooling caps during chemotherapy and extradiagnostic procedures, were not scored with the OPTION-5, but clinicians did receive feedback if considered relevant for applying SDM.

### Characteristics of consultations

A total of 139 consultations of patients with newly diagnosed breast cancer were recorded, including 80 consultations before and 59 after implementation. The mean number of recorded consultations was 1.8 (range 1–7) consultations per patient, with a mean (s.d.) duration of 47.7 (30.5) min per patient, and no difference between before (mean (s.d.) 46.0 (29.5) min) and after (50.1 (31.8) min) implementation (MD 2.3 (95 per cent c.i. –4.1 to 8.8) min). The SDM-Q-9 was completed by 105 patients: 72 questionnaires before and 33 after implementation (response rate 75.5 per cent). Seven questionnaires were excluded because patients left three or more items unanswered.

### OPTION-5 scores

The three raters reached acceptable levels of inter-rater agreement ($k = 0.57$, $k = 0.54$ and $k = 0.61$). Mean (s.d.) OPTION-5 scores increased from 38.3 (15.0) at baseline (80 patients) to 53.2 (14.8) (59 patients) after implementation (MD 14.9, 95 per cent c.i. 9.9 to

---

**Table 1 Refined scoring definitions for the OPTION-5 manual**

| Item | Description | Specification |
|------|-------------|---------------|
| 1    | The provider draws attention to, or reaffirms, a problem for which alternative treatment or management options exist, and that requires the initiation of a decision-making process. If the patient draws attention to the availability of options, and the provider responds by agreeing that the options need consideration, the item can also be scored positively | 0—not observed | 1—definition of the problem |
| 2    | The provider reassures the patient, or reaffirms, that they will support the patient in becoming better informed. The provider will support or explain the need to deliberate about the different options | 0—not observed | 1—decide together |
| 3    | The provider gives information, or reaffirms or checks understanding, about options that are considered reasonable (including taking no action), and supports the patient in understanding or comparing the pros and cons | 0—not observed | 1—listing the options |
| 4    | The provider supports the patient to examine, voice, and explore their personal preference in response to the options that have been described | 0—not observed | 1—exploring preferences |
| 5    | The provider makes an effort to integrate the patient’s preferences in terms of decisions that are either made by the patient or arrived at by a process of collaboration and discussion | 0—not observed | 1—definition of the problem |

10 audio recordings were coded by all three raters, and resulting scores and coding rules were discussed. Next, all audio recordings were scored independently by two raters. These scores were compared, and agreement over the final score was reached.

Unweighted Cohen’s $\kappa$ values were used to determine the inter-rater agreement.²⁴⁻⁵⁻
In this study, a multilevel implementation programme appeared to improve the adoption of SDM behaviour of clinicians, as observed during breast cancer consultations over time. This programme appears useful in the context of daily care, as five of the six hospital teams involved were able to participate fully in the programme while continuing their regular clinical care. Patients varied and different hospital teams (academic, teaching, and rural hospitals) comprising of team members from different clinical backgrounds (surgeons, nurses, nurse specialists) were included. Hence, the authors consider these results generalizable to any breast cancer treatment team.

This implementation programme was developed by using a four-level framework for designing an effective implementation strategy. It was grounded in relevant theoretical literature, to include promising elements that support the adoption of SDM by clinicians in daily practice. These elements are not a predetermined set of implementation activities, but were tailored to teams and clinicians, to facilitate alignment to diverging needs of the teams and individual clinicians with regard to SDM and time-out. For example, SDM attitudes, skills, and clinical pathways differ per clinician and team.

Baseline scores were relatively high, reflecting the present-day focus on communication with patients with breast cancer, compared with patients with other conditions, and a clinical condition for which multiple options are feasible. This was no barrier to further improvement, given the 15-point increase in OPTION-5 scores found after implementation. This increase is relatively high compared with that found in other studies, although a more intense implementation approach in palliative cancer care showed a larger increase in standardized patients.

Hospital team was associated with OPTION-5 scores. In most previous studies, researchers rated one consultation carried out by one clinician, whereas here the team performance per patient was rated. The implementation design responded to the needs of individual clinicians within the team and the local context. Each team defined its own goals and decided which tools to use to support SDM. Tailoring a programme to the team’s needs may evoke social support within the team to improve one another’s behaviour, as well as the intrinsic encouragement needed for sustainable behavioural change.

Providing time-out for patients in the decision-making process was an explicit element of the implementation programme. This was based on patient feedback during the implementation process and the findings of previous research indicating that application of SDM might require lengthier or additional consultations. This did not lead to an increase in either consultation time or mean number of consultations.

Patients did not perceive a higher level of SDM, a finding consistent with previous research. Patient satisfaction was found already to be high before implementation, in agreement with previous findings. Future research should focus on how SDM can be incorporated effectively into clinical practice by improving implementation designs, aligning implementation efforts better to the local context, and finding better ways to evaluate any influence on patients’ perceptions. To gain insight into which elements of the implementation programme are most helpful to support the change of clinicians, a logical next step is to investigate the relative contribution of each part of the implementation programme by a qualitative evaluation among study participants, and by monitoring the actual participation of each team and its team members. Patients often do not know what SDM entails and any communication of uncertainty might lead to dissatisfaction among women facing cancer decisions. It is therefore suggested that objective measurement of SDM, such as the OPTION-5 instrument, be included in future research.

Limitations of this study included the design without a control group. It was difficult to identify any other factors (unrelated to the implementation programme) that may have influenced SDM over time. Cluster randomization by hospital was considered, but found to be too expensive. Patients, clinicians, and investigators were not blinded to the intervention and the recordings, as the investigators had to provide relevant feedback as part of the consultation(s).
implementation. Clinicians may have attempted to provide optimal consultations, even though they were instructed to perform as usual. Previous studies, however, have indicated that audio recordings of the consultations have no significant effect on clinician behaviour\textsuperscript{52,53}. In addition, investigators may have been biased in their scoring of the OPTION-S, as they knew whether they were listening to preimplementation or postimplementation recordings.

Funding
Zilveren Kruis Healthcare Insurance Company
Dutch Ministry of Health, Welfare and Sport

Acknowledgements
This study is presented on behalf of the ‘Time-out study group’: E. Visserman and G. Boss (one of the raters) (Dutch Association of Oncology Patient Organizations); M. Schuurman and J. Oskam (Dutch Breast Cancer Patient Foundation); A. Doeksen and E. Schouten (Antonius Medical Centre Nieuwegein); E. Schoenmaeckers and D. van Odijk (Meander Medical Centre Amersfoort); A. Witkamp, T. Kempees and I. de Vries (University Medical Centre Utrecht); E. Vrients and E. Pompe (Tergooi Medical Centre Hilversum).

The authors thank all patients and clinicians for participating in this study and for giving the researchers the opportunity to use feedback from real-life consultations to help clinicians make better decisions together with their patients.

An unrestricted educational grant was provided by Zilveren Kruis Healthcare Insurance Company and the Dutch Ministry of Health, Welfare and Sport. In-kind support was provided by the participating hospitals.

Disclosure. The authors declare no conflict of interest.

Supplementary material
Supplementary material is available at BJS Open online.

References
1. National Institute for Public Health and the Environment. Breast Cancer in the Netherlands. https://www.rivm.nl/en/Topics/B/Breast_cancer_screening_programme/Breast_cancer_in_the_ Netherlands (accessed 1 June 2019)
2. Kessels RPC. Patients’ memory for medical information. J R Soc Med 2003;96:219–222
3. Sep MSC, Van Osch M, Van Vliet LM, Smets EMA, Bensing JM. The power of clinicians’ affective communication: how reassurance about non-abandonment can reduce patients’ physiologically arousing and increase information recall in bad news consultations. An experimental study using analogue patients. Patient Educ Couns 2014;95:45–52
4. Stiggebout AM, Van Der Weijden T, De Wit MPT, Frosch D, Légaré F, Montori VM et al. Shared decision making: really putting patients at the centre of healthcare. BMJ 2012;344:e256
5. Gattellari M, Butow PN, Tattersall MHN. Sharing decisions in cancer care. Soc Sci Med 2001;52:1865–878
6. Joseph-Williams N, Lloyd A, Edwards A, Stobart L, Tomson D, Macphail S et al. Implementing shared decision making in the NHS: lessons from the MAGIC programme. BMJ 2017;357:j1744
7. Légaré F, Thompson-Leduc P. Twelve myths about shared decision making. Patient Educ Couns 2014;96:281–286
8. Berger Z. Navigating the unknown: shared decision-making in the face of uncertainty. J Gen Intern Med 2015;30:675–678
9. Légaré F, Ratté S, Gravel K, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals’ perceptions. Patient Educ Couns 2008;73:526–535
10. Légaré F, Witteman HO. Shared decision making: examining key elements and barriers to adoption into routine clinical practice. Health Aff 2013;32:276–284
11. Elwyn G, Scholl I, Tietbohl C, Mann M, Edwards AG, Clay C et al. ‘Many miles to go’ a systematic review of the implementation of patient decision support interventions into routine clinical practice. BMC Med Inform Decis Mak 2013;13(Suppl 2):S14
12. van Veenendaal H, van der Weijden T, Ubbink DT, Stiggebout AM, van Mierlo LA, Hilders CGJM. Accelerating implementation of shared decision-making in the Netherlands: an exploratory investigation. Patient Educ Couns 2018;101:2097–2104
13. Politì MC, Clark MA, Ombao H, Dizon D, Elwyn G. Communicating uncertainty can lead to less decision satisfaction: a necessary cost of involving patients in shared decision making? Health Expect 2011;14:84–91
14. Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. CA Cancer J Clin 2014;64:377–388
15. Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP. Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer 2009;17:117–127
16. Coovvey JR, Kamal KM, Gorse EE, Mehta Z, Dhumal T, Heidari E et al. Barriers and facilitators to shared decision-making in oncology: a systematic review of the literature. Support Care Cancer 2019;27:1613–1637
17. Ménard C, Merckaert I, Razavi D, Libert Y. Decision making in oncology: a selected literature review and some recommendations for the future. Curr Opin Oncol 2012;24:381–390
18. Kunnenman M, Engelhardt EG, Laura Ten Hove FL, Marijnen CAM, Fortielle JEA, Smets EMA et al. Deciding about (neo-)adjuvant rectal and breast cancer treatment: missed opportunities for shared decision making. Acta Oncol 2016;55:134–139
19. Butow P, Juraskova I, Chang S, Lopez AL, Brown R, Bernhard J. Shared decision making coding systems: how do they compare in the oncology context? Patient Educ Couns 2010;78:261–268
20. Pieterse AH, Henselmans I, De Haes HCJM, Koning CCE, Geijsen AP. Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer 2014;22:338–342
21. Henselmans I, De Haes HCJM, Smets EMA. Enhancing patient participation in oncology consultations: a best evidence synthesis of patient-targeted interventions. Psychon Soc 2013;22:961–977
22. Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017;(4)CD001431
23. Henselmans I, van Laarhoven HVM, de Haes HCJM, Tokat M, Engelhardt EG, van Maarschalkerweerd FEA et al. Training for medical oncologists on shared decision-making about palliative chemotherapy: a randomized controlled trial. Oncologist 2019;24:259–265
